SHANDONG XINHUA (00719) has received a Drug Registration Certificate for its Entacapone Tablets from the National Medical Products Administration. According to the announcement dated 4 March 2026, the approved specification is 0.20g in tablet form, registered under Class 4 chemicals.

Entacapone Tablets serve as an adjunct to standard levodopa-based regimens, targeting Parkinson’s disease and end-dose phenomenon that cannot be managed by standard therapies alone. The product is included as a Category B treatment in the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2025).

Official data indicate that sales of Entacapone Tablets in China’s public medical institutions totaled approximately 286.00 million yuan in 2024. The management notes that this newly approved certificate will help enrich the company’s antiviral drug product lineup and strengthen its overall market competitiveness. However, the company points out that pharmaceutical sales may be influenced by changes in industry policies, bidding processes, and market conditions, signaling uncertainties in future performance.